Yen-Jung Chiu

Cell-line-derived and published transcriptomic signatures benchmarked against transcriptome-based clinical axes for neoadjuvant response prediction in breast cancer

Signatures from cell-line drug screens are deployed to patient transcriptomes to predict response. In breast cancer this may re-encode routine clinical variables rather than drug-specific biology. We tested whether ten transcriptomic signatures, scored without refitting, add pathological complete response...

Multicohort Evaluation of Acquisition Confounding in Single-Site Lung-CT Malignancy Classification with Frozen Foundation-Model Features.